Recent advances in our knowledge of viral hepatitis have rendered invalid the continuing custom of equating so-called "infectious hepatitis" with "hepatitis A" and of limiting the diagnosis of "hepatitis B" to those viral hepatitis patients in whose serum the surface antigen (HB.Ag) of hepatitis B virus (HBV) has been demonstrated during the first 10 days after onset of jaundice. While common source food-and waterborne outbreaks have been shown to be invariably caused by hepatitis A virus (HAV), such outbreaks account for only a small portion of icteric, viral hepatitis reported in recent years in the U.S. A. or communication) . Thus, the data that have been reported at this symposium on the incidence of hepatitis A and of hepatitis B in military personnel as well as similar reports by the Center for Disease Control (CDC, HEW) for the civilian population must be regarded as inaccurate and misleading in the absence of the tests for the HBV antibodies just mentioned and for the recently reported highly specific HAV antibodies that cannot as yet be carried out on a routine basis. What is urgently needed in civilian and military populations are well-planned, collaborative clinical and laboratory studies to determine how much of total icteric, viral hepatitis in persons of different ages and socioeconomic status are caused by HAV and HBV in different geographic areas.
The next question I wish to address is whether icteric, viral hepatitis is currently really much more frequent in military personnel than in civilians of comparable age and sex, or whether differences in reporting of this disease in the military and civilian populations prevent meaningful conclusions. In the military, there are records of patients with the icteric disease who are sick enough to seek help in military medical installations, and the main problem is that data based on admissions diagnosis may show smaller or larger numbers of cases than the more reliable discharge records, and using the date of discharge rather than of admission may result in different annual totals. With few exceptions, the differences are not too great. On the other hand, a recently reported study (1) on the greater New Haven civilian population during 1973-74 showed great variations in the completeness of reporting of viral hepatitis from 16.7% by private physicians, 28.1% by hospitals, and 55.6% by other health facilities. In this study it was also estimated that the annual incidence rates for this geographic region were about 100/100,000 for urban residents and 23/100,000 for suburban residents; certainly a marked difference from the 2007/100,000 in active duty USAREUR personnel in 1973, if one does not take into consideration the much higher proportion of viral hepatitis in young males in the U.S.A. in recent years.
The data in Fig. 1 Fig. 2 ).
There is no question that there is much more viral hepatitis among active duty U.S. Army personnel stationed in Europe than among personnel stationed in the U.S.A., and much more than among civilians in the U.S.A. and German civilians in Germany (see Table 1 ), no matter how big a proper correction factor for underreporting of civilian cases may be. It is of interest, however, to note that the usual seasonal incidence, as well as the unusual peak incidence in 1973 in U.S. Army personnel (Fig. 2) , corresponds exactly to that in the German civilian population of The increasing number of drug addicts and "dirty needle" transmission have been generally blamed for the marked increase in viral hepatitis among U.S. military personnel in Germany and elsewhere, but I find it difficult to accept this explanation as the main factor for a number of reasons. I cannot see how it can account for the seasonal incidence, especially the unusual summer peak in the 1973 epidemic (Fig. 2) . In November, 1973 a new hepatitis coding system adopted by the Army included information on both tests for HB, Ag and history of drug abuse within 8 In view of these findings one may question how much, if any of icteric, viral hepatitis in U.S. military personnel is caused by HAV (except for the occasional common source food-or water-borne outbreaks), and how much, if any, by the hypothetical hepatitis C virus (except some few cases post-transfusion). While the answer can come only from urgently needed well-planned studies in which the best available specific laboratory tests for HAV and HBV infection (and HCV? when and if available) will be used, the preliminary data now on hand strongly suggest (but do not establish) that HBV is currently the predominant viral cause of hepatitis in U.S. military personnel throughout the world.
One cannot think rationally about various potential methods of prevention of hepatitis B without consideration of our present knowledge of HBs Ag subtypes, and whether HBs Ag is the only surface antigen by which the HBV particle can attach itself to susceptible cells. Besides the common group antigen "a," HB, Ag has additional antigenic determinants of "d" or "y," and of "w" and "r" that are the phenotypic expressions of different HBV genotypes. The four known combinations of adw, ayw, adr, and ayr breed true on serial passages in humans and chimpanzees. Individual infections are as a rule caused by a single subtype; i.e., the HBs Ag recovered from any one patient or healthy carrier is usually adw, ayw, adr; ayr is very rare. The resulting HBs Ag antibodies correspond to the infecting subtypes and can be more readily used to determine the prevalence of infection (not disease) caused by the different subtypes in different population groups.
In the U.S.A. the HBs Ag recovered from healthy, volunteer blood donors is adw in 85% and ayw in 15%. The HBs Ag antibody in healthy persons without a history of hepatitis exhibits about the same proportion. A similar predominance of the subtype adw has been found in other parts of North America, in South America, in northern and western Europe, in South Africa, East Africa, Indonesia, the Philippines, Taiwan, and Hong Kong. A predominance of about 80 to 85% ayw vs 15-20% of adw has been found in Romania, Italy, Greece, Yugoslavia, Israel, Egypt, Iran, Pakistan, India, and West Africa. The borderline between adw and ayw in Africa is between Kenya and North Uganda. The subtype adr is predominant in Oceania, Thailand (83% adr vs 17% adw), Burma, The People's Republic of China, Korea, and the Kyushu and Honshu islands of Japan. The borderline between adw and adr predominance in Japan is between Kyushu and Okinawa. Some of the more recent data on the geographic distribution of HB, Ag subtypes given here are from the discussion by Dr. Kusuya Nishioka (4 (7). Thus, while both ad and ay subtypes of HBV can produce acute icteric hepatitis, the data cited above suggest the existence of pathogenic variants, with a higher frequency of virulent strains among those with the ay determinants. The situation may perhaps be comparable to the three types of poliovirus, all of which can produce paralytic disease in man; but over the years 90% of paralytic disease is caused by the type 1 virus. Recent work on the e antigen of HBV (8) .indicates that one cannot exclude the possibility that it is another HBV surface antigen, distinct from the HB, Ag spherical particle, and that antibody vs the e antigen may also play a protective role.
As regards prevention of viral hepatitis in U.S. military personnel, it seems to me that the immediate question is whether or not hepatitis immune gamma globulin, prepared by current techniques involving elimination of HB, Ag-containing blood, with known antibody content against various HBV antigens and against HAV should be used in a manner comparable to that employed in the [1967] [1968] [1969] field trial in Korea (9), i.e., 5 ml repeated at 5-to 7-month intervals during the period of service, or whether it should not be used until another trial, controlled for incidence of HAV and HBV hepatitis by modern techniques, is carried out in an area of especially high incidence.
According to information I received from Major John M. McLean, MSC, Epidemiologist (Office of The Surgeon General, Department of the Army) gamma globulin is now being used prophylactically in U.S. Army personnel in Korea once a year in the autumn. It was previously used during the period of [1964] [1965] [1966] [1967] [1968] [1969] and reintroduced in 1973 (with a recommendation that 5-ml doses be administered once every 6 months) when the hepatitis incidence more than doubled in 1970-72 after discontinuation of gamma globulin. It yet known that a large proportion of sporadic "infectious hepatitis" was caused by HBV, and also because of the ineffectiveness of conventional preparations against posttransfusion or post-"needle-stick" hepatitis. Maj. Gilbert Irwin has reviewed in this symposium several trials in which "standard" gamma globulin may have had an effect on naturally transmitted HBV infection not involving "needle sticks."
In my judgment, the assumption that most HBV hepatitis in U.S. military personnel is now transmitted by "needle sticks" is not supported by the available data, but on the basis of the amount of parenteral drug use still occurring in Armed Forces personnel a portion of the hepatitis is unquestionably so transmitted, and this would have to be taken into consideration in any policy decision. Since gamma globulin may only convert clinically apparent, icteric hepatitis into clinically inapparent infections, and since chronic hepatitis is more frequently associated with inapparent HBV infections, it is necessary to obtain some estimate of the risk of chronic hepatitis following inapparent HBV infection in reaching a decision on extensive use of gamma globulin for prevention of icteric HBV disease.
A decision on the use or study of gamma globulin in U.S. Army personnel in Europe cannot be postponed on the assumption that an effective HBV vaccine is "around the corner." The data obtained thus far with purified HB, Ag vaccine (devoid of e antigen) are very preliminary on very small numbers of chimpanzees. They as yet tell us nothing about duration of immunity, about the role of subtypes in crossimmunity when only HB, Ag is used, and about the hazards, if any, of repeated inoculations of such antigens if multiple boosters should be required. Trials on even the smallest numbers of human beings should, in my judgment, be postponed until the answers to these and other questions become available from more extensive studies on larger numbers of chimpanzees; all of which cannot be accomplished within a few years.
